Skip to main content
News

NIH rejects bid to cut a cancer drug’s price by sidestepping patents

By March 24, 2023No Comments
Nih logo 2101026093

INih logo 2101026093n a long-awaited decision, the National Institutes of Health rejected a petition urging the agency to use a controversial provision of federal law to widen access to a cancer drug by forcing the manufacturers to license their patents.

 

{iframe}https://www.statnews.com/pharmalot/2023/03/22/nih-cancer-patents-bayh-dole-xtandi/?utm_campaign=pharmalittle&utm_medium=email&_hsmi=251268307&utm_content=251268307&utm_source=hs_email{/iframe}

Leave a Reply

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.